Titlebook: Novel Therapeutics from Modern Biotechnology; From Laboratory to H Dale L. Oxender,Leonard E. Post (Vice President, D Book 1999 Springer-Ve

季雨

SB 209763: A Humanized Monoclonal Antibody for the Prophylaxis and Treatment of Respiratory Syncytif life. It is the dominant cause of severe lower respiratory-tract disease (bronchiolitis and pneumonia) in infants and young children, leading to approximately 100,000 hospitalizations each year in the United States alone (H. 1990). There are two major antigenically distinct subgroups of RSV, A and

insomnia

Bph773

sinoatrial-node

Safe, Efficient Production of Retroviral Vectors,ene marking. Lymphocytes were removed from a melanoma biopsy, expanded in vitro and transduced with a retroviral vector carrying a gene that conferred resistance to the neomycin analogue, G-418. The clinical objective was to determine the distribution and longevity of these marked lymphocytes. Short

大量

傳授知識

grenade

hysterectomy

Strategies for Dealing With the Immunogenicity of Therapeutic Proteins,istration of protein-based pharmaceuticals (Table 1). Minor differences in the primary structure of proteins—even as little as one amino acid from the human form of the protein—have been shown to be sufficient for immune system recognition.

osteocytes

0171-2004 supplementary material: A cover story of Business Week Magazine in January 1984 stated "Biotech Comes of Age". In February 1986, Venture Magazine had a cover article entitled "The Biotech Revolution is Here". This article went on to say "New Genetic Technologies Will Transform Our Lives". These anno

上流社會